atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
The UK Government’s announcement to be an AI superpower will impact every L&D professional’s future.
The UK government announced it’s AI Opportunities Action Plan, which has three key goals:
To lay the foundations for AI
To change lives by embracing AI
To secure the…
Tom Jackson highlights a recent report demonstrating how organisations can incorporate AI within their learning and development practices.
Organisations are using AI solutions to quickly craft tailored learning experiences for each team member and/or team need, making the learning process…
Attendees
Sponsors and
Exhibitors
AI Training
for Doctors Workshops
Contact us